Contineum reports Q2 2026 results, affirms IPF and MDD trial timelines

Contineum Therapeutics reported second-quarter 2026 results on July 30, 2026, and affirmed the status of its two lead clinical programs. CEO Carmine Stengone said the company has grown the footprint of PROPEL-IPF, its global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, to more than 55 sites across eight countries to keep enrollment moving.¹ He also said Johnson & Johnson finished enrolling patients in June for its Phase 2 "MOONLIGHT-1" trial testing JNJ-5120/PIPE-307 in major depressive disorder.¹

On the IPF program, patient dosing began in the first quarter of 2026 for PROPEL-IPF, a 26-week randomized, double-blind, placebo-controlled study testing once-daily oral PIPE-791 in about 324 IPF patients, with the primary endpoint measuring change in absolute forced vital capacity through week 26.¹ For MOONLIGHT-1, Johnson & Johnson completed enrollment of 107 adult participants in June 2026 in this placebo-controlled proof-of-concept trial evaluating JNJ-5120/PIPE-307 as monotherapy for MDD.¹

Separately, Contineum reported positive topline data on April 30, 2026, from an exploratory Phase 1b trial of PIPE-791 in chronic osteoarthritis or low back pain, meeting its safety and tolerability objective with an adverse event profile consistent with prior studies, and showing numerically greater pain improvement than placebo.¹

The company also said it has streamlined its discovery programs to focus on inflammatory and fibrotic disease candidates, resulting in a limited research workforce reduction that included Chief Scientific Officer Daniel Lorrain.¹

On finances, Contineum held $236.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it said is sufficient to fund operations through mid-2029.¹ Stengone added that this runway extends about one year past the estimated completion of the IPF trial.¹